EP1888106A4 - Zusammensetzungen und verfahren zur behandlung von ephrinsignalisierung mit cupredoxinen - Google Patents

Zusammensetzungen und verfahren zur behandlung von ephrinsignalisierung mit cupredoxinen

Info

Publication number
EP1888106A4
EP1888106A4 EP06813192A EP06813192A EP1888106A4 EP 1888106 A4 EP1888106 A4 EP 1888106A4 EP 06813192 A EP06813192 A EP 06813192A EP 06813192 A EP06813192 A EP 06813192A EP 1888106 A4 EP1888106 A4 EP 1888106A4
Authority
EP
European Patent Office
Prior art keywords
cupredoxins
compositions
methods
conditions related
treating conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06813192A
Other languages
English (en)
French (fr)
Other versions
EP1888106A2 (de
Inventor
Ananda Chakrabarty
Gupta Tapas Das
Tohru Yamada
Anita Chaudhari
Arsenio Fialho
Yonghua Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois
Original Assignee
University of Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/244,105 external-priority patent/US7691383B2/en
Application filed by University of Illinois filed Critical University of Illinois
Publication of EP1888106A2 publication Critical patent/EP1888106A2/de
Publication of EP1888106A4 publication Critical patent/EP1888106A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP06813192A 2005-05-20 2006-05-19 Zusammensetzungen und verfahren zur behandlung von ephrinsignalisierung mit cupredoxinen Withdrawn EP1888106A4 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68281205P 2005-05-20 2005-05-20
US11/244,105 US7691383B2 (en) 2004-10-07 2005-10-06 Cupredoxin derived transport agents and methods of use thereof
US76474906P 2006-02-03 2006-02-03
PCT/US2006/019684 WO2007018671A2 (en) 2005-05-20 2006-05-19 Compositions and methods for treating conditions related to ephrin signaling with cupredoxins

Publications (2)

Publication Number Publication Date
EP1888106A2 EP1888106A2 (de) 2008-02-20
EP1888106A4 true EP1888106A4 (de) 2009-01-14

Family

ID=37727776

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06813192A Withdrawn EP1888106A4 (de) 2005-05-20 2006-05-19 Zusammensetzungen und verfahren zur behandlung von ephrinsignalisierung mit cupredoxinen

Country Status (10)

Country Link
EP (1) EP1888106A4 (de)
JP (1) JP2008539795A (de)
KR (1) KR20080040631A (de)
AU (1) AU2006277009A1 (de)
BR (1) BRPI0612424A2 (de)
CA (1) CA2608512A1 (de)
IL (1) IL187138A0 (de)
MX (1) MX2007014598A (de)
NO (1) NO20076391L (de)
WO (1) WO2007018671A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691383B2 (en) 2004-10-07 2010-04-06 The Board Of Trustees Of The University Of Illinois Cupredoxin derived transport agents and methods of use thereof
US7556810B2 (en) 2005-07-19 2009-07-07 The Board Of Trustees Of The University Of Ilinois Compositions and methods to control angiogenesis with cupredoxins
US9096663B2 (en) 2001-02-15 2015-08-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
US7381701B2 (en) 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
EP1904642A4 (de) 2005-07-19 2008-11-26 Univ Illinois Transportmittel zur überquerung der blut-hirn-schranke und zum eindringen in gehirnkrebszellen sowie verwendungsverfahren dafür
WO2007024368A2 (en) * 2005-07-19 2007-03-01 The Board Of Trustees Of The University Of Illinois Compositions and methods to control angiogenesis with cupredoxins
BRPI0714987A2 (pt) * 2006-09-14 2013-07-30 Trutees Of The University Of Illinoi Board Of composiÇÕes e mÉtodos para a prevenÇço do cÂncer com cupredoxina
EP2117573A4 (de) * 2007-01-11 2011-02-16 Univ Illinois Zusammensetzungen und verfahren zur behandlung von ephrinsignalisierung mit cupredoxinen und mutanten davon
MY150621A (en) 2007-08-30 2014-02-14 Daiichi Sankyo Co Ltd Anti-epha2 antibody
KR101102829B1 (ko) * 2008-09-12 2012-01-05 재단법인 제주테크노파크 구멍갈파래 추출물과 그것의 항염증제로서의 용도
CN110090295B (zh) * 2018-01-29 2022-12-23 武汉康理通科技有限公司 Ephrin-B1在制备治疗炎症性肠病的药物中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002076380A2 (en) * 2001-02-15 2002-10-03 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
WO2005018662A1 (en) * 2003-08-15 2005-03-03 Board Of Trustees Of The University Of Illinois Use of polypeptides of the cupredoxin family in cancer therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002076380A2 (en) * 2001-02-15 2002-10-03 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US20060040269A1 (en) * 2001-02-15 2006-02-23 Chakrabarty Ananda M Cytotoxic factors for modulating cell death
WO2005018662A1 (en) * 2003-08-15 2005-03-03 Board Of Trustees Of The University Of Illinois Use of polypeptides of the cupredoxin family in cancer therapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HIMANEN J-P ET AL: "Eph signaling: a structural view", TRENDS IN NEUROSCIENCE, ELSEVIER, AMSTERDAM, NL, vol. 26, no. 1, 1 January 2003 (2003-01-01), pages 46 - 51, XP004398871, ISSN: 0166-2236 *
TOTH JOSEPH ET AL: "Crystal structure of an ephrin ectodomain", DEVELOPMENTAL CELL, vol. 1, no. 1, July 2001 (2001-07-01), pages 83 - 92, XP002505155, ISSN: 1534-5807 *
YAMADA TOHRU ET AL: "Bacterial redox protein azurin, tumor suppressor protein p53, and regression of cancer.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 99, no. 22, 29 October 2002 (2002-10-29), pages 14098 - 14103, XP002486971, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
MX2007014598A (es) 2008-02-07
NO20076391L (no) 2008-02-15
WO2007018671A2 (en) 2007-02-15
AU2006277009A1 (en) 2007-02-15
WO2007018671A3 (en) 2007-11-22
BRPI0612424A2 (pt) 2009-01-27
KR20080040631A (ko) 2008-05-08
EP1888106A2 (de) 2008-02-20
JP2008539795A (ja) 2008-11-20
CA2608512A1 (en) 2007-02-15
IL187138A0 (en) 2008-02-09

Similar Documents

Publication Publication Date Title
IL187138A0 (en) Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
AP2885A (en) Methods and compositions for improving plant health
EP1899480A4 (de) Zusammensetzungen und verfahren zur behandlung entzündlicher leiden
ZA200800187B (en) Methods for increasing the resistance of plants to hypoxic conditions
GB2469243B (en) Improvements in or relating to ablutionary installations
IL184698A0 (en) Composition and method for improving plant health
IL229039A0 (en) Solid preparations and methods for treating insomnia in the middle of the night
EP1895838A4 (de) Zusammensetzungen und verfahren
SI2137210T1 (sl) Nov postopek in sestavki
EP2101731A4 (de) Verfahren und zusammensetzungen mit endoxifen
EP2043671A4 (de) Verfahren und zusammensetzungen zur behandlung von apoplexie mit fieber
IL191237A0 (en) Compositions and methods for treating thrombocytopenia
IL197602A0 (en) Compositions and methods to prevent cancer with cupredoxins
EP2088865A4 (de) Guggulphospholipid-verfahren und zusammensetzungen
GB0617171D0 (en) Novel compositions and methods
ZA200710205B (en) Solid compositions and methods for treating middle-of-the night insomnia
EP2278984A4 (de) Zusammensetzungen und verfahren zur verbesserung der fertilität
GB0501348D0 (en) Compositions and methods
ZA200709939B (en) Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
EP2059122A4 (de) Verfahren und zusammensetzungen in verbindung mit der expression von apobec-1
GB0500224D0 (en) Improvements in or relating to ablutionary installations
GB0714599D0 (en) Composition and methods relating to photopolymer
EP2117573A4 (de) Zusammensetzungen und verfahren zur behandlung von ephrinsignalisierung mit cupredoxinen und mutanten davon
EP2032146A4 (de) Verfahren und zusammensetzungen für tr4
GB0503412D0 (en) Methods and compositions to treat glaucoma

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071123

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ZHU, YONGHUA

Inventor name: FIALHO, ARSENIO

Inventor name: CHAUDHARI, ANITA

Inventor name: YAMADA, TOHRU

Inventor name: DAS GUPTA, TAPAS

Inventor name: CHAKRABARTY, ANANDA

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20081202BHEP

Ipc: A61P 31/18 20060101ALI20081202BHEP

Ipc: A61K 38/16 20060101ALI20081202BHEP

Ipc: C07K 14/21 20060101ALI20081202BHEP

Ipc: C07K 14/195 20060101AFI20081202BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20081211

17Q First examination report despatched

Effective date: 20090326

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20121006